FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 17, 2017--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of
Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics,
with responsibility for Gilead’s hematology and oncology programs,
including cell therapy research and development. Dr. Riva will become a
member of Gilead’s senior leadership team.
Dr. Riva joined Gilead in January 2017 as Senior Vice President,
Hematology and Oncology Therapeutic Area Head. He has been instrumental
in expanding Gilead’s oncology program with the recent acquisition of
Kite Pharma, establishing the company as a leader in the field of
cellular therapy. He has also guided the strategy and development of
Gilead’s broader oncology pipeline during his tenure.
Prior to joining Gilead, Dr. Riva served as Head, Global Oncology
Development at Novartis, where he oversaw the development and worldwide
regulatory approval of multiple compounds in a variety of tumor types.
He received his bachelor’s degree in Medicine and a Certificate Board in
Oncology/Hematology from the School of Medicine of Milan. Earlier in his
career, he worked as a physician, treating patients with hematological
malignancies at the University Hospital of Milan.
“Alessandro’s vision and insight have helped Gilead broaden and deepen
our oncology pipeline through the acquisition of Kite Pharma, and his
exceptional leadership has guided the company’s broader
hematology/oncology strategy,” said John McHutchison, MD, Executive Vice
President, Clinical Research. “In his new role, I am confident that
Gilead’s hematology and oncology programs will continue to expand, as we
seek to advance new therapies with the potential to transform the
treatment of patients with cancer.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended June 30, 2017, as filed with
the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000
View source version on businesswire.com: http://www.businesswire.com/news/home/20171017005582/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792